{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:36:32Z","timestamp":1783056992510,"version":"3.54.6"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Epithelial ovarian cancer is chemotherapy responsive, and multiple lines of chemotherapy are often given. However, there are few data with regard to its effectiveness in later lines. Our aim was to assess its benefit in the high-grade, serous subtype relative to the line of therapy, using etoposide as the example.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Women treated with oral etoposide at the British Columbia Cancer Agency upon recurrence\/progression in the years 2000 to 2010 were reviewed. Kaplan-Meier and Cox regression methods were used to correlate line of therapy with overall survival, progression-free survival, and interval between etoposide initiation and next progression or death (EPFS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 219 women, median age 61, received etoposide as second (17%), third (30%), fourth (26%), fifth (17%), and sixth to eighth (11%) lines of therapy. The median number of cycles was 2 to 4. Patients who received etoposide as fourth-line to eighth-line treatment had a significantly longer median overall survival and initial progression-free survival (from diagnosis to first relapse) when compared with those who received it as second-line to third-line treatment (47.8 vs. 25.8 mo, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001; and 16.1 vs. 12.1 mo, <jats:italic toggle=\"yes\">P<\/jats:italic>&lt;0.0001, respectively); that is, a selected population of survivors received it later in the course of their disease. On univariate analysis, there was no significant difference in median EPFS (range, 2 to 2.9 mo) on the basis of line of therapy. On multivariate analysis, the hazard ratios improved through the third, fourth, and fifth lines (hazard ratios: 0.82, 0.77, and 0.34, respectively), and was statistically significant in the fifth line. The a priori-defined endpoint of clinical benefit was the \u201cpercentage not progressing at 3 months,\u201d and this was achieved in 32% to 48%.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In this retrospective study, a similar degree of benefit from etoposide, as defined by the percentage remaining progression free at 3 months, was seen in all lines of therapy.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000281","type":"journal-article","created":{"date-parts":[[2016,3,19]],"date-time":"2016-03-19T16:43:30Z","timestamp":1458405810000},"page":"379-384","source":"Crossref","is-referenced-by-count":2,"title":["Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer"],"prefix":"10.1097","volume":"41","author":[{"given":"Aalok","family":"Kumar","sequence":"first","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhu","family":"Le","sequence":"additional","affiliation":[{"name":"Cancer Control Research, British Columbia Cancer Agency, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Santos","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hoskins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230905","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.ygyno.2005.03.022","article-title":"Identifying patients unlikely to benefit from further chemotherapy: a descriptive study of outcome at each relapse in ovarian cancer","volume":"97","author":"Hoskins","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R2-20230905","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/IGC.0b013e3182049273","article-title":"Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube","volume":"21","author":"Griffiths","year":"2011","journal-title":"Int J Gynecol Ca"},{"key":"R3-20230905","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1093\/annonc\/mds203","article-title":"The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy","volume":"23","author":"Hanker","year":"2012","journal-title":"Ann Oncol"},{"key":"R4-20230905","first-page":"151","article-title":"Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications","volume":"27","author":"Kurman","year":"2008","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20230905","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2009.09.029","article-title":"Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications","volume":"116","author":"Kobel","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R6-20230905","first-page":"137","article-title":"Etoposide in cisplatin-refractory ovarian cancer (abstract 527)","volume":"7","author":"Kuhnle","year":"1988","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R7-20230905","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.1994.12.1.60","article-title":"Oral etoposide is active against platinum-resistant epithelial ovarian cancer","volume":"12","author":"Hoskins","year":"1994","journal-title":"J Clin Oncol"},{"key":"R8-20230905","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1038\/sj.bjc.6602427","article-title":"Phase I\/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer","volume":"92","author":"Baur","year":"2005","journal-title":"BJC"},{"issue":"suppl","key":"R9-20230905","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00003495-199958003-00007","article-title":"Oral etoposide for the treatment of recurrent ovarian cancer","volume":"58","author":"Ozols","year":"1999","journal-title":"Drugs"},{"key":"R10-20230905","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.7314\/APJCP.2012.13.8.3973","article-title":"Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology","volume":"13","author":"Kucukoner","year":"2012","journal-title":"Asian Pacific J Cancer Prev"},{"key":"R11-20230905","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.1998.16.2.405","article-title":"Prolong oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study","volume":"16","author":"Rose","year":"1998","journal-title":"J Clin Oncol"},{"key":"R12-20230905","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American society of clinical oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201804000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T23:33:27Z","timestamp":1693956807000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201804000-00010"}},"subtitle":["An Analysis of Outcomes Obtained With Oral Etoposide"],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000281","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}